Technical Breakdown, page-10

Nobody knows the trial result, people are probably selling to reduce their exposure to such a risky event. Its just risk management - I sold some in the 50s after buying in the 30s because why not take a profit and mitigate risk?

And the agitation trial was most likely added not because they think the PTSD trial will be negative, but because agitation is a lot easier to diagnose in patients than PTSD. Easier to diagnose = more scripts = more income.

Any trial relating to neurological problems is ridiculously difficult to nail, I am quite certain no drug in history has hit the CAPS-5 endpoint that 210 is trying to hit. It may come back negative, but it won't be the death of the company.